3/20
08:03 pm
lnth
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now? [Yahoo! Finance]
3/18
11:46 am
lnth
Lantheus says FDA extended review period for radioactive diagnostic kit [Seeking Alpha]
Low
Report
Lantheus says FDA extended review period for radioactive diagnostic kit [Seeking Alpha]
3/17
07:03 pm
lnth
Lantheus (LNTH) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Lantheus (LNTH) had its "outperform" rating reaffirmed by William Blair.
3/17
04:43 pm
lnth
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) [Yahoo! Finance]
Low
Report
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) [Yahoo! Finance]
3/17
04:39 pm
lnth
US FDA extends review of Lantheus' diagnostic imaging kit by three months [Yahoo! Finance]
Low
Report
US FDA extends review of Lantheus' diagnostic imaging kit by three months [Yahoo! Finance]
3/17
04:05 pm
lnth
Lantheus (LNTH) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Lantheus (LNTH) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/17
04:01 pm
lnth
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Low
Report
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
3/17
08:26 am
lnth
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? [Yahoo! Finance]
Medium
Report
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? [Yahoo! Finance]
3/15
01:05 am
lnth
Low
Report
3/12
10:16 am
lnth
Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight [Yahoo! Finance]
Low
Report
Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight [Yahoo! Finance]
3/12
07:05 am
lnth
3 Reasons to Sell LNTH and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Sell LNTH and 1 Stock to Buy Instead [Yahoo! Finance]
3/11
10:10 am
lnth
Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & Supplies - Imaging, Diagnostics Stocks [Yahoo! Finance]
Low
Report
Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & Supplies - Imaging, Diagnostics Stocks [Yahoo! Finance]
3/9
05:25 pm
lnth
Why Lantheus Holdings Stock Popped by Almost 12% Last Month [Yahoo! Finance]
Medium
Report
Why Lantheus Holdings Stock Popped by Almost 12% Last Month [Yahoo! Finance]
3/6
04:44 pm
lnth
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection [Yahoo! Finance]
Medium
Report
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection [Yahoo! Finance]
3/6
04:01 pm
lnth
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Medium
Report
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
3/2
12:19 pm
lnth
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Low
Report
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
3/2
08:54 am
lnth
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® [Yahoo! Finance]
Low
Report
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® [Yahoo! Finance]
3/2
08:30 am
lnth
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Low
Report
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
3/1
05:13 pm
lnth
Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Rebound And PYLARIFY Outlook [Yahoo! Finance]
Low
Report
Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Rebound And PYLARIFY Outlook [Yahoo! Finance]
2/27
06:00 pm
lnth
Lantheus (LNTH) was given a new $89.00 price target by Truist Financial Corporation.
Low
Report
Lantheus (LNTH) was given a new $89.00 price target by Truist Financial Corporation.
2/27
01:11 pm
lnth
Lantheus (LNTH) had its price target raised by Mizuho from $72.00 to $85.00. They now have an "outperform" rating on the stock.
Low
Report
Lantheus (LNTH) had its price target raised by Mizuho from $72.00 to $85.00. They now have an "outperform" rating on the stock.
2/27
08:02 am
lnth
Lantheus (LNTH) had its "hold" rating reaffirmed by JonesTrading.
Low
Report
Lantheus (LNTH) had its "hold" rating reaffirmed by JonesTrading.
2/26
05:33 pm
lnth
Lantheus Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Lantheus Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
03:03 pm
lnth
Lantheus (LNTH) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Lantheus (LNTH) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/26
12:47 pm
lnth
Lantheus (LNTH) was upgraded by William Blair from "market perform" to "outperform".
Low
Report
Lantheus (LNTH) was upgraded by William Blair from "market perform" to "outperform".